Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

Buprenorphine

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines1

Latest

Everything in the corpus, newest first.

JUN 18, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Buprenorphine Transdermal System (REMS)

U.S. Food and Drug Administration

FDA supplemental approval for buprenorphine transdermal system REMS; regulatory action without reported clinical trial outcomes.

Regulatory UpdateBuprenorphine Strides Pharma Intl

Reported

Approval date2026-06-18

Application numberANDA207490

Approved dosage strengths5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 20 mcg/hr

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support